ATNX - Athenex, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
11.34
+0.40 (+3.66%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.94
Open11.01
Bid0.00 x 900
Ask0.00 x 900
Day's Range10.79 - 11.49
52 Week Range9.83 - 20.90
Volume250,060
Avg. Volume258,674
Market Cap760.047M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GuruFocus.com23 days ago

    Weekly CEO Buys Highlight

    Details the CEO buys this past week for the following companies: Continental Resources, New Fortress Energy, Athenex, FS KKR Capital and Federal Agricultural Mortgage

  • GuruFocus.com26 days ago

    Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares

    Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The price of the stock has decreased by 0.16% since.

  • GuruFocus.comlast month

    Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $141,240 of Shares

    Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Warning! GuruFocus has detected 3 Warning Signs with ATNX.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT

    Q4 2018 Athenex Inc Earnings Call

  • American City Business Journalslast month

    The moment Athenex executives and investors have been waiting for is almost here

    Results from the Phase 3 study of Athenex's leading drug candidate will be published in the middle of this year, potentially signaling to the world the arrival of its technology.

  • Athenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript
    Motley Foollast month

    Athenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript

    ATNX earnings call for the period ending December 31, 2018.

  • Associated Presslast month

    Athenex: 4Q Earnings Snapshot

    On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported ...

  • MarketWatch2 months ago

    Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints

    Shares of biotech Athenex, Inc. rose 3.8% in premarket trade Monday after the company announced that two Phase 3 studies of KX2-391, an ointment for the treatment of actinic keratosis, had met their primary endpoints. Actinic keratosis is a skin condition caused by exposure to the sun's ultraviolet rays, resulting in patches of thick, scaly skin. Left untreated, the lesions can progress to skin cancer. In one study of 351 patients, 44% of patients receiving KX2-391 cleared their actinic keratosis lesions after 57 days, compared with 5% of those in the control group. In the second study, also of 351 patients, 54% of patients getting the treatment cleared their lesions, compared with 13% of patients in the control group. Side effects were mild to moderate, the company said, and were usually local skin reactions causing itchiness or pain. Shares of Athenex have fallen 16.3% in the year to date, while the S&P 500 has gained 4.2%.

  • Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
    Zacks3 months ago

    Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

    Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

  • Athenex Completes Enrollment Target for Breast Cancer Study
    Zacks3 months ago

    Athenex Completes Enrollment Target for Breast Cancer Study

    Athenex (ATNX) has completed target enrollment in the Oraxol phase III study in metastatic breast cancer on schedule.

  • Buffalo startups surpassed $200 million in VC and angel funding in 2018
    American City Business Journals3 months ago

    Buffalo startups surpassed $200 million in VC and angel funding in 2018

    The number was inflated by the surging ACV Auctions, an online platform for wholesale car auctions, which was founded in 2014 and closed Series C and D venture capital rounds last year that totaled $124 million. It is undoubtedly the biggest story in Buffalo tech, but it’s not the sole reason 2018 was a record-breaking year. The portfolio of startups that received funding in Buffalo last year reflect the city’s economic diversity, along with the development strategies of recent years.

  • American City Business Journals4 months ago

    Teresa Bair talks about the big year ahead for Athenex

    The fast-growing drug development company expects to data this year on its two leading chemotherapy drugs. The pharmaceutical world is watching.

  • What Kind Of Shareholders Own Athenex, Inc. (NASDAQ:ATNX)?
    Simply Wall St.4 months ago

    What Kind Of Shareholders Own Athenex, Inc. (NASDAQ:ATNX)?

    A look at the shareholders of Athenex, Inc. (NASDAQ:ATNX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...

  • Company News For Dec 13, 2018
    Zacks4 months ago

    Company News For Dec 13, 2018

    Companies In The News Are: AEO,PVTL,LOW,ATNX

  • GuruFocus.com5 months ago

    Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $117,500 of Shares

    CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 10,000 shares of ATNX on 11/19/2018 at an average price of $11.75 a share.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ATNX earnings conference call or presentation 14-Nov-18 1:00pm GMT

    Q3 2018 Athenex Inc Earnings Call

  • Associated Press5 months ago

    Athenex: 3Q Earnings Snapshot

    The Buffalo, New York-based company said it had a loss of 70 cents per share. Losses, adjusted for non-recurring costs, came to 33 cents per share. The biopharmaceutical company posted revenue of $18.4 ...

  • Thomson Reuters StreetEvents8 months ago

    Edited Transcript of ATNX earnings conference call or presentation 14-Aug-18 1:00pm GMT

    Q2 2018 Athenex Inc Earnings Call

  • Associated Press8 months ago

    Athenex: 2Q Earnings Snapshot

    On a per-share basis, the Buffalo, New York-based company said it had a loss of 58 cents. The biopharmaceutical company posted revenue of $11.6 million in the period. Athenex expects full-year revenue ...

  • Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year?
    Zacks9 months ago

    Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year?

    Is (ATNX) Outperforming Other Medical Stocks This Year?

  • A Focus on Pipeline Expansion Bodes Well for Athenex
    Market Realist9 months ago

    A Focus on Pipeline Expansion Bodes Well for Athenex

    Athenex entered a joint venture with Xiangxue Life Sciences for developing and commercializing T-cell receptor engineered cells (or TCR-T). TCR-T is a cancer immunotherapy technology based on the novel approach to high-affinity TCR developed by Xiangxue Life Sciences.

  • Athenex’s Product Groups and Geographic Performance
    Market Realist9 months ago

    Athenex’s Product Groups and Geographic Performance

    The majority of Athenex’s revenues in the first quarter came from API sales, commercial product sales, and license fees. License fees and consulting revenues showed the biggest increase, rising from $598,000 in the first quarter of 2017 to $25.01 million in the first quarter.

  • A Look at Athenex’s Research Pipeline
    Market Realist9 months ago

    A Look at Athenex’s Research Pipeline

    Athenex (ATNX) believes its ability to overcome challenges associated with the oral delivery of chemotherapy and intravenous delivery through its P-gp inhibitor could offer key potential benefits for patients. These developments could help patients stay on therapy longer, extending the potential to combine with other targeted therapies and immunotherapies that would otherwise be too toxic in combination with chemotherapy. Athenex’s orascovery platform is based on the P-gp pump inhibitor molecule HM30181A, which the company had in-licensed from Hanmi Pharmaceuticals in 2011. Coadministering this molecule with oral paclitaxel is designed to facilitate the oral absorption of paclitaxel.

  • How Athenex’s Business Segments Performed in Q1 2018
    Market Realist9 months ago

    How Athenex’s Business Segments Performed in Q1 2018

    Athenex (ATNX) operates in three business segments—Oncology Innovative Platform, Global Supply Chain Platform, and Commercial Platform. Athenex’s Oncology Innovative Platform segment performs proprietary drug research and development. While the segment had incurred a net loss of $28.26 million in the first quarter of 2017, in the first quarter it generated net income of $1.51 million.